Tweet
J Cardiothorac Vasc Anesth
. 2020 Sep 4;S1053-0770(20)30862-4.
doi: 10.1053/j.jvca.2020.08.067. Online ahead of print.
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation
Zhen Guo 1 , Lin Sun 1 , Bailing Li 2 , Rui Tian 3 , Xiaolin Zhang 4 , Zhongwei Zhang 5 , Sean P Clifford 6 , Yuan Liu 7 , Jiapeng Huang 8 , Xin Li 9
Affiliations
- PMID: 32994131
- DOI: 10.1053/j.jvca.2020.08.067
Abstract
Objective: To explore special coagulation characteristics and anticoagulation management in extracorporeal membrane oxygenation (ECMO)-assisted patients with coronavirus disease 2019 (COVID-19).
Design: Single-center, retrospective observation of a series of patients.
Participants: Laboratory-confirmed severe COVID-19 patients who received venovenous ECMO support from January 20-May 20, 2020.
Interventions: This study analyzed the anticoagulation management and monitoring strategies, bleeding complications, and thrombotic events during ECMO support.
Measurements and main results: Eight of 667 confirmed COVID-19 patients received venovenous ECMO and had an elevated D-dimer level before and during ECMO support. An ECMO circuit pack (oxygenator and tubing) was replaced a total of 13 times in all 8 patients, and coagulation-related complications included oxygenator thrombosis (7/8), tracheal hemorrhage (5/8), oronasal hemorrhage (3/8), thoracic hemorrhage (3/8), bleeding at puncture sites (4/8), and cannulation site hemorrhage (2/8).
Conclusions: Hypercoagulability and secondary hyperfibrinolysis during ECMO support in COVID-19 patients are common and possibly increase the propensity for thrombotic events and failure of the oxygenator. Currently, there is not enough evidence to support a more aggressive anticoagulation strategy.
Keywords: COVID-19; ECMO; SARS-CoV-2; anticoagulation; coronavirus; extracorporeal membrane oxygenation; severe acute respiratory syndrome coronavirus 2; thrombosis.